Krystin Prasad
Family · Toms River, NJNPI 1477974939
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,525 of the $14,095 with a category attached, or 60.5%. AbbVie accounts for 73.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $5,119 and has fallen 76.3% since, to $1,212 in 2025. Among family clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 354 payments — averaging $39.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Axsome Therapeutics, Inc.$469
- Takeda Pharmaceuticals U.S.A., Inc.$429
- Alkermes, Inc.$286
- Otsuka America Pharmaceutical, Inc.$255
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$8,52560%
- Food & beverage$5,50539%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 117 | $10,315 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 74 | $1,130 |
| Axsome Therapeutics, Inc. | 19 | $469 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $429 |
| Alkermes, Inc. | 20 | $286 |
| Otsuka America Pharmaceutical, Inc. | 16 | $255 |
| Supernus Pharmaceuticals, Inc. | 11 | $204 |
| Johnson & Johnson | 13 | $202 |
| Vanda Pharmaceuticals Inc. | 10 | $152 |
| Sunovion Pharmaceuticals Inc. | 9 | $127 |
| Corium, LLC | 8 | $104 |
| Almatica Pharma LLC | 6 | $90 |
| Eisai Inc. | 6 | $78 |
| Lundbeck LLC | 6 | $78 |
| Bausch Health US, LLC | 4 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Reapplix Inc. | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,095 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 60 | $106,853 |
| LybalviOlanzapine/Samidorphan Malate | 23 | $51,218 |
| RexultiBrexpiprazole | 29 | $42,684 |
| TrintellixVortioxetine Hydrobromide | 34 | $27,033 |
| Aripiprazole | 256 | $19,182 |
| FanaptIloperidone | 13 | $14,792 |
| Bupropion XlBupropion Hcl | 376 | $8,226 |
| Duloxetine Hcl | 466 | $7,554 |
| Fluoxetine Hcl | 663 | $6,922 |
| Quetiapine Fumarate | 360 | $6,394 |
| Trazodone Hcl | 406 | $5,787 |
| Alprazolam | 732 | $5,507 |
| Escitalopram Oxalate | 403 | $4,421 |
| Oxcarbazepine | 79 | $4,071 |
| Sertraline Hcl | 397 | $3,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $10,315 | $106,85360 claims |
| Alkermes, Inc.Lybalvi | $286 | $51,21823 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $255 | $42,68429 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $429 | $27,03334 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $152 | $14,79213 claims |
| Almatica Pharma LLCSertraline Hcl | $90 | $3,998397 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.
Other family in Toms River
- Shawn DenningToms River$29K
- Jamie LarsonToms River$10K
- Kristen LewisToms River$9K
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.